A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT ID: NCT06914895
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
905 participants
INTERVENTIONAL
2025-04-25
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tirzepatide Dose 1
Participants will receive tirzepatide subcutaneously (SC)
Tirzepatide
Administered SC
Tirzepatide Dose 2
Participants will receive tirzepatide SC
Tirzepatide
Administered SC
Tirzepatide Dose 3
Participants will receive tirzepatide SC
Tirzepatide
Administered SC
Tirzepatide Dose 4
Participants will receive tirzepatide SC
Tirzepatide
Administered SC
Placebo
Participants will receive placebo SC
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirzepatide
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have an HbA1c value of 7.0% to 10.5% inclusive, at screening
* Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening
* Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study
Exclusion Criteria
* Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.
* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
* Have had chronic or acute pancreatitis
* Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sansum Diabetes Research Institute
Goleta, California, United States
Care Access - Santa Clarita
Santa Clarita, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Atlanta Diabetes Associates
Atlanta, Georgia, United States
Orita Clinical Research
Decatur, Georgia, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Indiana University Health University Hospital
Indianapolis, Indiana, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Endocrine and Metabolic Consultants
Rockville, Maryland, United States
HealthPartners Institute dba International Diabetes Center
Minneapolis, Minnesota, United States
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi, United States
Boeson Research MSO
Missoula, Montana, United States
Palm Research Center Tenaya
Las Vegas, Nevada, United States
Palm Research Center Sunset
Las Vegas, Nevada, United States
Albany Medical College, Division of Community Endocrinology
Albany, New York, United States
Research Foundation of SUNY - University of Buffalo
Buffalo, New York, United States
NYC Research
New York, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Lucas Research, Inc.
Morehead City, North Carolina, United States
Care Access - Lima
Lima, Ohio, United States
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Suburban Research Associates
West Chester, Pennsylvania, United States
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Tekton Research, LLC.
McKinney, Texas, United States
Medrasa Clinical Research
Wylie, Texas, United States
Eastside Research Associates
Redmond, Washington, United States
Rainier Clinical Research Center
Renton, Washington, United States
Investigaciones Medicas Imoba Srl
Buenos Aires, , Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, , Argentina
CIPREC
Buenos Aires, , Argentina
Consultorio de Investigación Clínica EMO SRL
Buenos Aires, , Argentina
CENUDIAB
Buenos Aires, , Argentina
Instituto de Investigaciones Clínicas Córdoba
Córdoba, , Argentina
Centro Medico Privado San Vicente Diabetes
Córdoba, , Argentina
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, , Argentina
Instituto Médico Río Cuarto
Río Cuarto, , Argentina
Fundacion Estudios Clinicos
Rosario, , Argentina
Centro de Diagnóstico y Rehabilitación (CEDIR)
Santa Fe, , Argentina
Centro de Salud e Investigaciones Médicas
Santa Rosa, , Argentina
Centro de Diabetes Curitiba
Curitiba, , Brazil
Centro De Diabetes Metabolismo E Endocrinologia
Fortaleza, , Brazil
Private Practice - Dr.Miguel N. Hissa
Fortaleza, , Brazil
Universidade Federal de Goias
Goiânia, , Brazil
CPQuali Pesquisa Clínica
São Paulo, , Brazil
CPCLIN
São Paulo, , Brazil
IBTED - Tecnologia e Educação em Diabetes
São Paulo, , Brazil
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, , Brazil
Hospital das Clinicas FMUSP
São Paulo, , Brazil
CEDOES
Vitória, , Brazil
Esbjerg sygehus, Syddansk Universitetshospital
Esbjerg, , Denmark
Steno Diabetes Center - Copenhagen
Herlev, , Denmark
Regionshospitalet Gødstrup
Herning, , Denmark
Nordsjællands Hospital - Hillerød
Hillerød, , Denmark
Sjællands Universitetshospital Køge
Køge, , Denmark
Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre
Caen, , France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, , France
Hôtel-Dieu du Creusot - site Harfleur
Le Creusot, , France
Centre du diabète DIAB-eCARE
Lyon, , France
Hôpital Européen Marseille
Marseille, , France
Hôpital de la Conception
Marseille, , France
CHU Montpellier Lapeyronie Hospital
Montpellier, , France
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
Nantes, , France
Hôpital NOVO
Pontoise, , France
CHU Strasbourg-Hautepierre
Strasbourg, , France
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
Toulon, , France
CHU Rangueil
Toulouse, , France
Groupe Hospitalier Mutualiste Les Portes du Sud
Vénissieux, , France
Diabetespraxis Mergentheim
Bad Mergentheim, , Germany
Diabetes- und Stoffwechselpraxis Bochum
Bochum, , Germany
InnoDiab Forschung Gmbh
Essen, , Germany
Diabetes Zentrum Wilhelmsburg
Hamburg, , Germany
Klinikum Karlsburg
Karlsburg, , Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
Institut für Diabetesforschung GmbH Münster
Münster, , Germany
RED-Institut GmbH
Oldenburg, , Germany
Arztpraxis Christine Kosch Pirna
Pirna, , Germany
Yitzhak Shamir Medical Center
Beer Yaacov, , Israel
Soroka Medical Center
Beersheba, , Israel
Rambam Health Care Campus
Haifa, , Israel
Institute of Diabetes, Technology and Research - Clalit Health
Herzliya, , Israel
Hadassah Medical Center
Jerusalem, , Israel
Schneider Children's Medical Center
Petah Tikva, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Diabetes Medical Center
Tel Aviv, , Israel
Sourasky Medical Center
Tel Aviv, , Israel
IRCCS - AOU di Bologna
Bologna, , Italy
AOU Renato Dulbecco
Catanzaro, , Italy
Azienda Ospedaliera Universitaria Careggi
Florence, , Italy
Ospedale San Raffaele
Milan, , Italy
University of Naples Federico II
Napoli, , Italy
Azienda Ospedale - Università Padova
Padua, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, , Italy
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Torino, , Italy
The Institute of Medical Science, Asahi Life Foundation
Chūōku, , Japan
Matoba Internal Medicine Clinic
Ebina, , Japan
Clinic Masae Minami
Fukuoka, , Japan
Japanese Red Cross Fukuoka Hospital
Fukuoka, , Japan
Hachioji Diabetes Clinic
Hachioji-shi, , Japan
Takai Internal Medicine Clinic
Kamakura-shi, , Japan
Shiraiwa Medical Clinic
Kashiwara, , Japan
Kasugai Municipal Hospital
Kasugai, , Japan
Kimitsu Chuo Hospital
Kisarazu, , Japan
Yamanashi Prefectural Central Hospital
Kofu, , Japan
Kumamoto Central Hospital - Kumamoto
Kumamoto, , Japan
Jinnouchi Hospital
Kumamoto, , Japan
Kure Medical Center
Kure, , Japan
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, , Japan
Kozawa Eye Hospital and Diabetes Center
Mito, , Japan
Heiwadai Hospital
Miyazaki, , Japan
Soleil Chikusa Clinic
Nagoya, , Japan
Tosaki Clinic for Diabetes and Endocrinology
Nagoya, , Japan
Nakakinen clinic
Naka, , Japan
Osaka City General Hospital
Osaka, , Japan
Abe Clinic
Ōita, , Japan
Odori Diabetes
Sapporo, , Japan
Manda Memorial Hospital
Sapporo, , Japan
Shimonoseki Medical Center
Shimonoseki, , Japan
Tomonaga Clinic
Shinjuku, , Japan
Suruga Clinic
Shizuoka, , Japan
Tama Center Clinic Mirai
Tama, , Japan
Noritake Clinic
Ushiku, , Japan
Japanese Red Cross Society - Wakayama Medical Center
Wakayama, , Japan
Enclifar Ensayos Clínicos Farmacológicos Sc
Chihuahua City, , Mexico
Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente
Guadalajara, , Mexico
Centro de Investigacion Medica de Occidente, S.C.
Guadalajara, , Mexico
Unidad de Investigación Clínica y Atención Médica HEPA S.C.
Guadalajara, , Mexico
Invecordis S.C.
Hacienda de Las Palmas, , Mexico
CEINV Salud
Monterrey, , Mexico
Clínica García Flores SC
Monterrey, , Mexico
Consultorio Médico de Endocrinología y Pediatría
Puebla City, , Mexico
Medsal Centro Médico
Tampico, , Mexico
Advanced Clinical Research, LLC
Bayamón, , Puerto Rico
Manati Center for Clinical Research
Manatí, , Puerto Rico
CHUAC-Complejo Hospitalario Universitario A Coruña
A Coruña, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval
Ferrol, , Spain
Hospital Universitario de Móstoles
Móstoles, , Spain
Hospital Universitario Marqués de Valdecilla
Santander, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Phone: 1-317-615-4559
Email: [email protected]
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I8F-MC-GPJA
Identifier Type: OTHER
Identifier Source: secondary_id
2024-519684-17-00
Identifier Type: CTIS
Identifier Source: secondary_id
27285
Identifier Type: -
Identifier Source: org_study_id